摘要
目的观察口服正元胶囊联合应用信迪利单抗及化疗对晚期非小细胞肺癌(NSCLC)的临床效果。方法晚期NSCLC患者40例分为两组,每组20例,分别采用正元胶囊+信迪利单抗+化疗治疗(A组)和信迪利单抗+化疗治疗(B组)。21 d为1个疗程。治疗4个疗程后,比较两组临床疗效、生活质量(QOL)评分和免疫指标(CD3^(+)、CD4^(+)和CD8^(+)T淋巴细胞)变化;记录治疗期间不良反应发生情况。结果治疗4个疗程后,A组的客观缓解率和疾病控制率均稍高于B组(55%vs.40%和85%vs.75%)(P>0.05)。两组治疗前的CD3^(+)、CD4^(+)T淋巴细胞水平和CD4^(+)/CD8^(+)T淋巴细胞比例无统计学差异(P>0.05);治疗4个疗程后,B组CD3^(+)、CD4^(+)T淋巴细胞水平和CD4^(+)/CD8^(+)T淋巴细胞比例较治疗前降低,而A组CD3^(+)、CD4^(+)T淋巴细胞水平和CD4^(+)/CD8^(+)T淋巴细胞比例较治疗前升高,且高于B组(P<0.05)。治疗前,A组QOL评分与B组相仿[(27.54±3.54)分vs.(28.11±2.98)分](P>0.05);治疗后,A组QOL评分高于B组[(48.22±5.25)分vs.(43.16±4.24)分](P<0.05)。治疗期间,A组乏力、食欲下降和恶心呕吐发生率低于B组(P<0.01)。结论加服正元胶囊有利于提高信迪利单抗和化疗治疗晚期NSCLC的疗效,能提升患者的免疫功能,减少不良反应,改善晚期NSCLC患者的生存质量。
Objective To observe the clinical efficacy of oral Zhengyuan capsule combined with the use of sintilimab and chemotherapy for the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 40 patients with advanced NSCLC were assigned into two groups with 20 cases each,who were treated with oral Zhengyuan capsule combined with the use of sintilimab and chemotherapy(group A)and with sintilimab and chemotherapy(group B)for four therapeutic courses(21 days as one course).The clinical efficacy,quality of life(QOL)score and immune function indexes(CD3^(+),CD4^(+)and CD8^(+)T lymphocyte)were compared between the two groups.The adverse responses during treatment were recorded.Results The objective remission rate and the disease control rate of group A were slightly higher than those of group B after treatment(55%vs.40%and 85%vs.75%)(P>0.05).The levels of CD3^(+)and CD4^(+)T lymphocyte,and the ratio of CD4^(+)to CD8^(+)T lymphocyte before treatment were not significantly different between the two groups,which after treatment for four courses were decreased in group B and were increased in group A compared to before treatment(P<0.05).The levels of CD3^(+)and CD4^(+)T lymphocyte,and the ratio of CD4^(+)to CD8^(+)T lymphocyte after treatment for four courses were significantly higher in group A than those in group B(P<0.05).The QOL score of groups of A and B was similar before treatment[(27.54±3.54)points vs.(28.11±2.98)points](P>0.05),which after treatment for four courses was higher in group A than that in group B[(48.22±5.25)points vs.(43.16±4.24)points](P<0.05).During the treatment period,the incidence rates of fatigue,decreased appetite,and nausea and vomiting were significantly lower in group A than those in group B(P<0.01).Conclusion In the treatment of the patients with advanced NSCLC with sintilimab and chemotherapy,additionally oral Zhengyuan capsules is helpful in improving therapeutic efficacy and can enhance the immune function,reduce adverse responses and improve the QOL of the patients wit
作者
张楚
方成
朱丽娜
ZHANG Chu;FANG Cheng;ZHU Lina(Department of Oncology,Changzhou First People's Hospital,Changzhou 213100,CHINA)
出处
《江苏医药》
CAS
2022年第6期586-589,共4页
Jiangsu Medical Journal
关键词
信迪利单抗
非小细胞肺癌
正元胶囊
免疫治疗
Sintilimab
Non-small cell lung cancer
Zhengyuan capsule
Immunotherapy
